Chronic Plaque Psoriasis Market was valued at USD 24.5 billion in 2024 and is projected to reach USD 43.8 billion by 2034

Chronic Plaque Psoriasis Market Overview
The Chronic Plaque Psoriasis Market was valued at USD 24.5 billion in 2024 and is projected to reach USD 43.8 billion by 2034, growing at a CAGR of around 6.2%. Growth is fueled by rising disease prevalence, strong uptake of biologics, and continuous expansion of dermatology specialty care.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71377

Key Market Drivers
• Increasing global prevalence of moderate to severe plaque psoriasis.
• Rapid adoption of biologic therapies targeting IL-17, IL-23, and TNF-α pathways.
• Expansion of dermatology centers and improved patient access to specialty treatments.
• Strong clinical outcomes improving patient preference for biologics over topical/steroid therapies.

Challenges
• High cost of biologic treatments.
• Need for long-term therapy and continuous monitoring.
• Limited adoption in low-income regions due to affordability issues.

Market Segmentation
By Drug Class
• IL-17 inhibitors
• IL-23 inhibitors
• TNF-α inhibitors
• PDE4 inhibitors
• Topical therapies & corticosteroids

By Treatment Type
• Biologics
• Small molecules
• Topical treatments

By Severity
• Mild
• Moderate
• Severe

By End User
• Hospitals
• Dermatology clinics
• Homecare/self-administration

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71377/chronic-plaque-psoriasis-market

Regional Snapshot
• North America leads due to high biologic penetration and strong reimbursement systems.
• Europe shows stable growth supported by guideline-based psoriasis care and biosimilar adoption.
• Asia-Pacific is the fastest-growing region due to rising diagnosis and increased acceptance of biologics and biosimilars.

Key Companies
AbbVie, Novartis, Amgen, Eli Lilly, Johnson & Johnson, UCB, Pfizer, Bristol-Myers Squibb, Leo Pharma, Sun Pharma.

Future Outlook
The market will continue expanding as next-generation IL-23 and IL-17 biologics, biosimilars, and advanced topical agents gain wider adoption. Earlier diagnosis, improved treatment adherence tools, and personalized dermatology care will further accelerate growth over the next decade.

This report is also available in the following languages : Japanese (慢性尋常性乾癬市場), Korean (만성 플라크 건선 시장), Chinese (慢性斑块状银屑病市场), French (Marché du psoriasis en plaques chronique), German (Markt für chronische Plaque-Psoriasis), and Italian (Mercato della psoriasi a placche cronica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71377

Our More Reports:

Alcoholic Hepatitis Market
https://exactitudeconsultancy.com/reports/71269/alcoholic-hepatitis-market

Angioimmunoblastic T-Cell Lymphoma Market
https://exactitudeconsultancy.com/reports/71271/angioimmunoblastic-t-cell-lymphoma-market

Atypical Hemolytic Uremic Syndrome Market
https://exactitudeconsultancy.com/reports/71273/atypical-hemolytic-uremic-syndrome-market

Chronic Venous Insufficiency Market
https://exactitudeconsultancy.com/reports/71275/chronic-venous-insufficiency-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.